A revised concept of anaplastic large cell lymphoma (ALCL) on both historical and practical grounds is presented. The main histological findings are illustrated with special reference to the cytological spectrum that is characteristic of the tumor. The phenotype is described in detail. The expression of the ALK protein as well as the chromosomal abnormalities that sustain it, are discussed along with potential pathogenetic implications. The clinical features of ALCL are presented by underlying the dramatic difference in terms of response to therapy and survival between ALK-positive and ALK-negative forms. The possibility of limiting the term ALCL to systemic ALK+ anaplastic tumors with T/null phenotype is considered.
Anaplastic large cell lymphoma (ALCL) represents 2-3% of all lymphoid neoplasms, according to World Health Organization (WHO) estimatest. In children, ALCL makes up to 20-30% of lymphoid neoplasms1.
Originally described by Stein et al. in 19852, categorizations of this malignancy have undergone a series of revisions, which have led to a more refined and restrictive definition of the process3. DEFINITION The International Lymphoma Study Group (ILSG) first3 and the WHO later1 stated that the term ALCL should be applied to tumors with a T-cell or null phenotype, thus modifying the definition originally given in 19852. The latter reflected the way by which the neoplasm had been identified. Following the production of the Ki-1 monoclonal antibody4, Stein and co-workers validated the hypothesis that it specifically reacted with Hodgkin and ReedSternberg cells (HRSC) of Hodgkin's Lymphoma (HL)2. In the process, they showed that besides HRSC, the antibody stained activated normal B-and T-lymphocytes, a variety of non-Hodgkin's lymphomas, and a group of tumors that in the past had often been interpreted as metastatic undifferentiated carcinoma or malignant histiocytosis2. The latter cases consisted of very large cells with kidneyshaped nuclei, rod-shaped nucleoli, and a wide rim of deeply basophilic cytoplasm, which tended to produce a cohesive growth pattern and to diffuse through sinuses ( Fig. 1: a) 5. They all expressed the Ki-1 molecule (later included in the 30th cluster of lymphoid differentiation antigens and termed CD30), but displayed variable phenotypes (B-cell, T-cell, null, or hybrid)5. Further studies revealed the presence of recurrent chromosomal abnormalities among ALCL with T/null phenotype (see below), which were never detected among B-cell tumors, including those with an anaplastic profile6. At present, there is broad consensus that lymphomas showing anaplastic morphology, but carrying a B-cell phenotype, represent a subtype of diffuse large B-cell. lymphoma (DLBCL) that do not significantly differ on clinicopathologic grounds from other tumors within this category7. In addition, most authors tend to discard the term "Ki-1 cell lymphoma"8,9, used in the late eighties as a synonym for ALCL, as it refers to a phenotypic attribute which is shared by many other lymphoid tumors (e. g. most Hodgkin's lymphoma and some peripheral T-cell lymphomas unspecified, nodal marginal zone lymphomas, and follicular lymphomas). The Revised EuropeanAmerican Lymphoma (REAL) Classification3 and the WHO scheme derived from it1 have further refined the concept of ALCL, by limiting it to T/ null-cell tumors with systemic presentation.
The forms with limited cutaneous involvement have been included within the group of CD30+ lymphoproliferative disorders of the skin, because of their distinctive clinical behavior10. Tumors with anaplastic morphology, but secondary to another lymphoma (e. g. Hodgkin'
lymphoma, mycosis fungoides, peripheral T-cell lymphoma), are regarded as progression of the originally diagnosed process and should not be diagnosed as ALCL1,3
MORPHOLOGY
With time, it has become evident that ALCL is not sustained by a unique histotype, but actually includes several morphologic variants (classical, giant cell-rich, lymphohistiocytic, small-cell type, and mixed) ( Fig. 1 : a-h)6. Classical ALCL corresponds to the description of the tumor given by Stein and co-workers in 1985 ( Fig. 1: a) (see above)2. The giant cell-rich type is characterized by several multinucleated elements, often provided with ReedSternberg-like features and prominent intrasinusoidal diffusion ( Fig. 1: b) 6. The small and lymphohistiocytic variants11,12 display a marked variability in neoplastic cell size that ranges from small to large (Fig. 1: c-d ). The main difference between the two forms consists of a huge amount of reactive histiocytes with eccentric nuclei in the latter ( Fig. 1: c) 6. Such a reactive population tends to obscure the neoplastic component ( Fig. 1: c inset) and can lead to a misdiagnosis of hyper-immune reaction12. Interestingly, transition from one histotype to another has been recorded within the same node (mixed variant) or in different nodes taken from the same patient at the time of diagnosis or at relapse. These modifications might correspond to intra-clonal modulation or differential interactions between the tumor and micro-environment13. Further variants have been reported in the literature including signet-ring cell-like, epitheliod cell-rich, sarcomatoid, and eosinophil-rich ( Fig. 1: e-g)14-17. These are very rare and may indeed represent a diagnostic challenge. Finally, the so-called ALCL of the Hodgkin-like type deserves special attention'8. It was originally described as a form of the tumor, presenting in young people with a bulky mediastinal mass and consisting of anaplastic cells arranged in nodules surrounded by sclerotic bands (Fig. 1: h) , as seen in nodular sclerosing Hodgkin's lymphoma (NSHL)19-24 Following the introduction of the REAL Classification3, which regarded it as a provisional entity, this diagnosis was by no means also applied to cases of aggressive HL that could not be easily differentiated from ALCL, both on morphologic and phenotypic grounds18. This led to a diffuse skepticism regarding the existence of such a variant. It was considered a collection of tumors that could not be classified rather than as a specific entity and was thus not listed in the WHO scheme. In reality, bona fide examples of ALCL of the Hodgkin's-like type have been described. These are characterized by A L K protein-expression, homogeneous CD30-positivity, lack of CD 15 and B-cell activator protein (BSAP), possible T-cell antigen expression, and variable positivity for the leukocyte common antigen/CD45 and epithelial membrane 
MOLECULAR AND CYTOGENETIC FINDINGS
The t(2; 5) (p23; q35) was originally described in patients with malignant histiocytosis (MH)73,74 These actually represent ALCL cases diagnosed according to dated criteria. In fact, it soon became evident that this translocation characteristically occurred in ALCL75,76. At the beginning, the real incidence of this phenomenon was uncertain. The need for fresh or frozen material for cytogenetic studies or Southern blot analysis prevented a systematic analysis77. This aberration produced a hybrid gene, formed by the segment of the ALK gene encoding the transmembrane portion of the corresponding kinase and the NH2-terminal region of the NPM gene78. Under physiologic conditions, the latter encodes nucleophosmin, a shuttle-protein that undergoes dimerization in the cytoplasm and subsequently moves to the nucleus18,25,79. Due to the production of highly specific (polyclonal and monoclonal) antibodies raised against the transmembranic portion of the ALK protein, as well as the NH2-and COOH-terminal regions of NPM, the identification of the chimeric NPM/ALK protein (also termed p80 because of its molecular weight) became easily feasible in routine samples (formalin-fixed, paraffinembedded)6,42,80,81 This allowed the determination that a large majority of cases diagnosed as ALCL according to the REAL/WHO Classification do carry t(2; 5). The staining produced by the anti-ALK antibodies is typically cytoplasmic and nuclear, because the NPM/ALK protein forms heterodimers with normal NPM which, like normal NPM homodimers, is shuttled to the nucleus82. Unexpectedly, the broad application of monoclonal antibodies to ALK1 and ALKc revealed that about 10% of ALK-positive ALCLs showed an immunohistochemical reactivity confined to the cytoplasm. This was concomitant with the detection of a series of additional translocations (commonly called variant translocations), all involving the ALK gene, leading to the formation of a chimeric gene with partners other than NPM45. The derived hybrid proteins, all cause ALK overexpression and more often under oligomerization, but have no shuttling properties, and thus remain confined to the cytoplasm45. The most relevant of these variant translocations are the 43, 45, 64, 65 In particular, several studies have shown that about 90% of ALK+ ALCLs achieve complete remission (CR) with anthracyclincontaining regimens. Follow-up studies revealed that most patients are actually cured. In contrast, no more than 35% of ALK-cases obtain stable CR by the same therapies6,25,45,64,65, suggesting that more aggressive strategies including autologous or allogenic bone-marrow/stem cell transplantation should be adopted. This is not the only significant clinical difference between ALK-positive and negative ALCLs. In fact, the former most frequently occur among patients in the first or second decade of life, while the latter are usually recorded among people aged 50-7064. According to a recent report, leukemic spread seems to represent the only exception to the favorable prognosis of ALK+ ALCL90. Based on these findings, ten Berge et al. have recently suggested that the distinction between ALK-negative ALCL and prognosis of peripheral T-cell lymphoma, unspecified (PTCL/U) is of limited clinical relevance, with only age and the International Prognostic Index (IPI) being prognostically significant for these tumors64. As to the latter parameter, one should remember that it also has a prognostic impact within the ALK-positive ALCL group. In fact, the 5 year-overall survival is 94% and 41% for the cases with low/low-intermediate The monoclonal antibody ALK 1 identifies a distinct morphological subtype of anaplastic large cell
